What question did this study set out to answer?

To identify a minimal effective dose of vigabatrin for infantile spasms that minimizes drug exposure overlap with failure-associated doses while reducing the risk of exposure-related retinal toxicity.

September 7, 2018The Journal of Clinical Pharmacology

Proposition of a Minimal Effective Dose of Vigabatrin for the Treatment of Infantile Spasms Using Pediatric and Adult Pharmacokinetic Data

View Full Paper

Ask AI

Bookmark

To identify a minimal effective dose of vigabatrin for infantile spasms that minimizes drug exposure overlap with failure-associated doses while reducing the risk of exposure-related retinal toxicity.
Developed a population pharmacokinetic model of active S(+)-vigabatrin in 28 pediatric patients (aged 0.4–5.7 years) using Monolix software alongside an allometrically scaled adult model.
Characterized drug disposition with a one-compartment model incorporating zero-order absorption, first-order elimination, and weight-based empirical allometry.
Performed Monte Carlo simulations to assess exposure overlap between candidate dosing regimens and the 36-mg/kg daily dose associated with treatment failure.
Estimated pediatric apparent clearance at 2.36 L/h (24.5% interindividual variability), apparent volume of distribution at 17 L (38% interindividual variability), and absorption duration at 0.682 hours.
Demonstrated via Monte Carlo simulations that a daily dose of 80 mg/kg minimizes exposure overlap with the 36-mg/kg failure threshold in both pediatric and scaled adult models.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Pharmacokinetic modeling study identifies an 80 mg/kg daily minimal effective dose of vigabatrin for infantile spasms, suggesting lower risks of both treatment failure and retinal toxicity.

Cite This Study

Ounissi et al. (2018) studied this question.

synapsesocial.com/papers/6a899af240fe6a3effcb1547 https://doi.org/10.1002/jcph.1309

View Full Paper

Ask AI

Bookmark

Implication

Pharmacokinetic modeling study identifies an 80 mg/kg daily minimal effective dose of vigabatrin for infantile spasms, suggesting lower risks of both treatment failure and retinal toxicity.

Proposition of a Minimal Effective Dose of Vigabatrin for the Treatment of Infantile Spasms Using Pediatric and Adult Pharmacokinetic Data

Key Points

Discussion

Implication

Cite This Study

Proposition of a Minimal Effective Dose of Vigabatrin for the Treatment of Infantile Spasms Using Pediatric and Adult Pharmacokinetic Data

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider